Copper-Mediated Late-stage Radiofluorination: Five Years of Impact on Pre-clinical and Clinical PET Imaging.
Jay S WrightTanpreet KaurSean PreshlockSean S TanzeyWade P WintonLiam S SharninghausenNicholas WiesnerAllen F BrooksMelanie S SanfordPeter J H ScottPublished in: Clinical and translational imaging (2020)
CMRF has significantly expanded the chemical space that is accessible to fluorine-18 radiolabeling with production methods that can meet the regulatory requirements for use in Nuclear Medicine. Furthermore, it has enabled novel and improved syntheses of radiopharmaceuticals and facilitated subsequent PET imaging studies. The rapid adoption of CMRF will undoubtedly continue to simplify the production of imaging agents and inspire the development of new radiofluorination methodologies.